CoChat

Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

Newbold, Andrea, Matthews, Geoffrey M., Bots, Michael, Cluse, Leonie A., Clarke, Christopher J.P., Banks, Kellie-Marie, Cullinane, Carleen, Bolden, Jessica E., Christiansen, Ailsa J., Dickins, Ross A., Miccolo, Claudia, Chiocca, Susanna, Kral, Astrid M., Ozerova, Nicole D., Miller, Thomas A., Methot, Joey L., Richon, Victoria M., Secrist, J. Paul, Minucci, Saverio, Johnstone, Ricky W. · 2013 · Molecular Cancer Therapeutics
Cited by 46

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Histone deacetylase inhibitors (HDACi) are anticancer agents that induce hyperacetylation of histones, resulting in chromatin remodeling and transcriptional changes. In addition, nonhistone proteins, such as the chaperone protein Hsp90, are functionally regulated through hyperacetylation mediated by HDACis. Histone acetylation is thought to be primarily regulated by HDACs 1, 2, and 3, whereas the acetylation of Hsp90 has been proposed to be specifically regulated through HDAC6. We compared the molecular and biologic effects induced by an HDACi with broad HDAC specificity (vorinostat) with agents that predominantly inhibited selected class I HDACs (MRLB-223 and romidepsin). MRLB-223, a potent inhibitor of HDACs 1 and 2, killed tumor cells using the same apoptotic pathways as the HDAC 1, 2, 3, 6, and 8 inhibitor vorinostat. However, vorinostat induced histone hyperacetylation and killed tumor cells more rapidly than MRLB-223 and had greater therapeutic efficacy in vivo. FDCP-1 cells dependent on the Hsp90 client protein Bcr-Abl for survival, were killed by all HDACis tested, concomitant with caspase-dependent degradation of Bcr-Abl. These studies provide evidence that inhibition of HDAC6 and degradation of Bcr-Abl following hyperacetylation of Hsp90 is likely not a major mechanism of action of HDACis as had been previously posited. Mol Cancer Ther; 12(12); 2709–21. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-13-0626

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 46

Metadata

Authors
Newbold, A., Matthews, G. M., Bots, M., Cluse, L. A., Clarke, C. J. P., Banks, K.-M., Cullinane, C., Bolden, J. E., Christiansen, A. J., Dickins, R. A., Miccolo, C., Chiocca, S., Kral, A. M., Ozerova, N. D., Miller, T. A., Methot, J. L., Richon, V. M., Secrist, J. P., Minucci, S., & Johnstone, R. W.
Venue
Molecular Cancer Therapeutics
Published
2013-12-01
Volume
12
Issue
12
Pages
2709-2721
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2059540635
Cited by
46
References
11
FWCI
2.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0626
The paper
Newbold, A., Matthews, G. M., Bots, M., Cluse, L. A., Clarke, C. J. P., Banks, K.-M., Cullinane, C., Bolden, J. E., Christiansen, A. J., Dickins, R. A., Miccolo, C., Chiocca, S., Kral, A. M., Ozerova, N. D., Miller, T. A., Methot, J. L., Richon, V. M., Secrist, J. P., Minucci, S., & Johnstone, R. W. (2013). Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0626

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.